TORECAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is an injectable small-molecule drug approved by Novartis in 1961 with an unknown mechanism of action and indication profile. The specific therapeutic use and patient population cannot be determined from available data. As a legacy product, it represents a mature asset in the Novartis portfolio.
LOE Approaching
Loss of exclusivity is imminent; expect reduced team investment and transition to lifecycle management or product discontinuation planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORECAN offers minimal career advancement opportunity given its LOE trajectory and zero linked job openings. Roles available are primarily defensive, focused on managed decline, generic preparation, and supply continuity rather than growth or innovation.
Brand Manager (Lifecycle Management)Field Sales (Defensive)
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.